Join
Live feed
·
PRReleasevia Quantisnow
Vir Biotechnology Inc. logo

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
VIR· Vir Biotechnology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VIR (Vir Biotechnology Inc.) and more on Quantisnow.